Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Diagnosis

Improved diagnosis, therapy and outcomes for patients with CUP

Nature Reviews Clinical Oncology volume 14, pages 5–6 (2017)Cite this article

Subjects

Molecular cancer-classifier assays enable the diagnosis of a single cancer type for most patients with cancer of unknown primary (CUP), thus opening the door to the administration of site-specific therapies. Herein, I discuss how such therapies can improve the survival of patients with CUP, and the resulting paradigm shift towards tissue-of-origin diagnostics and treatments that is now becoming the standard of care for this patient population.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Pentheroudakis, G. Golfinopoulos, V. & Pavlidis, N. Switching benchmarks in cancer of unknown primary: from autopsy to microarray. Eur. J. Cancer 43, 2026–2036 (2007).

    Article  Google Scholar 

  2. Greco, F. A. & Hainsworth, J. D. in Cancer: Principles and Practice of Oncology 10th edn (eds DeVita, V. T., Lawrence, T. S. & Rosenberg, S. A.) 1720–1737 (Lippincott Williams and Wilkins, 2014).

    Google Scholar 

  3. Hainsworth, J. D. & Greco, F. A. Gene expression profiling in patients with carcinoma of unknown primary site: from translational research to standard of care. Virchows Arch. 464, 393–402 (2014).

    Article  CAS  Google Scholar 

  4. Ettinger, D. S. et al. Occult primary, version 3.2014. J. Natl Compr. Canc. Netw. 12, 969–974 (2014).

    Article  Google Scholar 

  5. Greco, F. A., Lennington, W. J. Spigel, D. R. & Hainsworth, J. D. Molecular profiling diagnosis in unknown primary cancer: accuracy and ability to complement standard pathology. J. Natl Cancer Inst. 105, 782–790 (2013).

    Article  CAS  Google Scholar 

  6. Moran, S. et al. Epigenetic profiling to classify cancer of unknown primary: a multicenter, retrospective analysis. Lancet Oncol. 17, 1386–1395 (2016).

    Article  Google Scholar 

  7. Hainsworth, J. D. et al. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon Research Institute. J. Clin. Oncol. 31, 217–223 (2013).

    Article  CAS  Google Scholar 

  8. Yoon, H. H. et al. Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0187 (alliance). Ann. Oncol. 27, 339–344 (2016).

    Article  CAS  Google Scholar 

  9. Hainsworth, J. D., Schnabel, C. A. Erlander, M. G. Haines, D. W. & Greco, F. A. A retrospective study of treatment outcomes in patients with carcinoma of unknown primary site and a colorectal molecular profile. Clin. Colorectal Cancer. 11, 112–118 (2012).

    Article  Google Scholar 

  10. Greco, F. A., Lennington, W. J., Spigel, D. R. Varadhachary, G. R. & Hainsworth, J. D. Carcinoma of unknown primary site: outcomes in patients with a colorectal molecular profile treated with site specific chemotherapy. J. Cancer Ther. 3, 37–43 (2012).

    Article  CAS  Google Scholar 

  11. Varadhachary, G. R. et al. Carcinoma of unknown primary with gastrointestinal profile: immunohistochemistry and survival data for this favorable subset. Int. J. Clin. Oncol. 19, 479–484 (2014).

    Article  CAS  Google Scholar 

  12. Greco, F. A., Lennington, W. J. Spigel, D. R. & Hainsworth, J. D. Poorly differentiated neoplasms of unknown primary site: diagnostic usefulness of a molecular cancer classifier assay. Mol. Diagn. Ther. 19, 91–97 (2015).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. F. Anthony Greco is at the Sarah Cannon Cancer Center, Tennessee Oncology, 250 25th Avenue North Suite 100, Nashville, Tennessee 37203, USA.,

    F. Anthony Greco

Authors
  1. F. Anthony Greco
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F. Anthony Greco.

Ethics declarations

Competing interests

F.A.G. is on the Speakers' Bureau and serves as a consultant for Biotheranostics, Inc.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Greco, F. Improved diagnosis, therapy and outcomes for patients with CUP. Nat Rev Clin Oncol 14, 5–6 (2017). https://doi.org/10.1038/nrclinonc.2016.194

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2016.194

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer